Our model in which MYCN selectively activates canonical MYC targets through binding promoters and represses cell lineage-specific differentiation genes through binding enhancers more fully rationalizes the different oncogenic cellular effects driven by MYCN in different types of cancer cells. This evidence concerns the gene MYCN and cancer.